Analysts Adjust Price Targets for Regeneron Pharmaceuticals

BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well

Bayer reported Q3 2026 core EPS of 11 cents, missing estimates of 13 cents, with a 36.7% year-over-year decline. Sales rose 4.1% to $11.57 billion but fell short of the $11.70 billion consensus. The Pharmaceuticals division drove growth with Nubeqa surging 58.3% and Kerendia jumping 64.9%, while Crop Science faced headwinds from weather and regulatory challenges. Bayer raised its 2026 EBITDA guidance, reflecting stronger pharmaceutical profitability.

Wall Street Analysts Update Ratings and Price Targets for Regeneron Pharmaceuticals

Multiple financial institutions updated their investment ratings and price targets for Regeneron Pharmaceuticals, Inc. on November 3, 2026.

Regeneron Announces Management Participation in Upcoming Investor Conferences

Regeneron Pharmaceuticals has scheduled management participation for three upcoming healthcare investor conferences in late 2026.

Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

RBC Capital Markets Adjusts Regeneron Pharmaceuticals Price Target to $913

RBC Capital Markets raised its price target for Regeneron Pharmaceuticals to $913 from $810 while maintaining a 'Sector Perform' rating.

These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results

Regeneron beat Q3 estimates with EPS up 70% and revenue up 36%; analysts raised price targets to as high as $1,175.